ALung Technologies Forms Trial Steering Committee

15 November 2016 Press Release, Recent News

Renowned physicians will oversee landmark trial of the Hemolung RAS in patients with COPD. PITTSBURGH (November 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the formation of its Trial Steering Committee (TSC) for its upcoming pivotal trial (read more)

Update on the Hemolung FDA Expedited Access Pathway process

14 June 2016 Recent News

In 2015, we announced that the Hemolung RAS had been selected by the FDA for its new Expedited Access Pathway (EAP) program. This new program aims to reduce the time and cost of market approval for breakthrough medical technologies aimed at addressing significant unmet clinical needs. The program promises to help accomplish this through things (read more)

New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

ALung’s artificial lung technology selected for use in landmark respiratory failure trial

2 December 2015 Press Release

The Hemolung Respiratory Assist System will be exclusively utilized in the 1120-patient study. PITTSBURGH  (December 2, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today its participation in the world’s first and largest pivotal trial of ECCO2R technology. The (read more)

The use of extracorporeal carbon dioxide removal to avoid intubation in patients failing non-invasive ventilation – a cost analysis

25 November 2015 Clinical Update, Recent News

  Background To evaluate the economic implications of the pre-emptive use of extracorporeal carbon dioxide removal (ECCO2R) to avoid invasive mechanical ventilation (IMV) in patients with hypercapnic ventilatory insufficiency failing non-invasive ventilation (NIV). Methods Retrospective ancillary cost analysis of data extracted from a recently published multicentre case–control-study (n = 42) on the use of arterio-venous ECCO2R to (read more)

Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure

Dr. Ravi Tiruvoipati presented the initial Australian experience with low-flow extracorporeal carbon dioxide removal (Hemolung RAS) at the 2015 Australian and New Zealand Intensive Care Society (ANZICS) meeting. Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure from alungtech (read more)

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study.

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study FJ Parrilla*, L Bergesio, H Aguirre-Bermeo, JC Suarez, P López, I Morán, J Mancebo From ESICM LIVES 2015 Berlin, Germany. 3-7 October 2015 Summary: Objective: To evaluate the effect of extracorporeal CO2 removal in ARDS during ultraprotective ventilation in terms of (read more)

“Low-flow” versus “mid-flow” extracorporeal CO2 removal: A review of clinical performance and device efficiency

25 November 2015 White Papers

Analysis of published clinical studies using approved veno-venous ECCO2R devices shows that the Hemolung RAS can provide the same amount of CO2 removal as traditional “mid-flow” ECCO2R devices. (read more)

ALung Technologies Receives Expedited Access Pathway Designation from FDA for Hemolung Respiratory Assist System

4 November 2015 Press Release

Designation will facilitate introduction of breakthrough respiratory technology in the United States Pittsburgh, PA (November 4, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today that its Hemolung Respiratory Assist System (RAS) has received Expedited Access Pathway (EAP) designation (read more)

How ActivMix Technology Enhances CO2 Removal in the Hemolung RAS

16 October 2015 White Papers

By ALung Technologies, Inc. The Hemolung Respiratory Assist System (RAS) is the only extracorporeal CO2 removal system that has been specifically designed to provide the safest, simplest and most efficient ECCO2R therapy. Other systems are non-integrated, modified ECMO or dialysis arrangements, and as such, have neither the level of safety, simplicity, nor efficiency of the (read more)